Gilead Sciences’ Remdesivir Data Release Brings Much Needed Relief for Patients and Investors
Gilead Sciences’ Remdesivir Data Release Brings Much Needed Relief for Patients and Investors 1For years, Gilead Sciences’ (NASDAQ:GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company’s revenues have experienced an enormous decline from 2015 onwards, falling over $10 billion in the past four years as patients cured of …
News story posted on 2020-04-16T17:43:00.0000000Z